Biogen Inc. has achieved a notable 21% earnings beat in the first quarter of 2026, reporting adjusted earnings per share of $3.57, exceeding expectations. The company also generated total revenue of $2.48 billion, surpassing consensus forecasts, while announcing its acquisition of Apellis Pharmaceuticals for $5.6 billion to enhance its growth trajectory. Despite this strong performance, Biogen has adjusted its full-year profitability guidance downward, anticipating a mid-single-digit revenue decline compared to the previous year.
“Biogen · posted a · +21% earnings beat · $3.57 per share”
“Biogen · posted earnings beat of · +21% · $3.57 per share versus $2.95 anticipated”
“Biogen · reported · total revenue for the first quarter of 2026 · $2.48 billion”
“Biogen's total revenue · compared to · consensus prognosticator forecast · $2.25 billion”
“Biogen's attributable net income · rose by · 19% · $529 million”
“Biogen's earnings per share · was · $3.57 · per share”
“Biogen · lowered · full-year profitability guidance · $14.25 to $15.25 per share”
“Biogen · is currently acquiring · Apellis Pharmaceuticals · $5.6 billion”
“Biogen Inc · reported · a strong start to 2026”
“Blood-based biomarkers · are growing in use · particularly in a PCP pilot with Biogen and Eisai”
“Biogen · continues to pivot away from · traditional strength in multiple sclerosis treatments”
“Biogen · published its latest set of · quarterly earnings”
